Over the past decade, molecular-targeted therapies have been added to cytotoxic and anti-
endocrine drugs in the treatment of cancer, with the aim to target the molecular pathways …

Despite enormous capital investments in biomedical research and bioengineering,
treatment modalities for prostate cancer patients have remained very much unchanged for …

Simple Summary Advanced prostate cancer that has progressed after standard therapies
such as hormone therapy and taxane-based chemotherapies is an invariably lethal disease …

The use of tyrosine kinase inhibitors (TKIs) in the treatment of solid tumors is the expected
standard of care for many types of tumors. Since the description of signal transduction …

New molecular insight reveals novel points of attack for targeted cancer therapy. The recent
advances in cancer genomics and novel insight into the complex biology of cancer make the …

Background Single drug use has not achieved satisfactory results in the treatment of
prostate cancer, despite application of increasingly widespread targeted therapeutics. In the …

Over the past 15 years, numerous signal transduction pathways have been elucidated
whose dysregulation may play an important role in the growth and survival of cancer cells …

Targeted therapies have often given disappointing results when used as single agents in
solid tumors, suggesting the importance of devising rational combinations of targeted drugs …

Cancer is the second leading cause of death worldwide, just behind cardiovascular
diseases. In fact, there was an estimated 18.1 million new cancer cases and 9.6 million …

Receptor tyrosine kinases (RTK) are key signaling molecules in regulating cancer cell
growth and are important cancer drug targets. Despite the success of specific RTK-targeting …